"The price of greatness is responsibility." Sir Winston Churchill


Search the IBPA



IBPA Issues
About IBPA
IBPA Constitution
FAQ-s
IBPA Events
Individual Membership
Institutional Membership
IBPA Forums / Groups
Cooperation with IBPA
Links

Publications
IBPA Careers Newsletter
Past Issues
Industry Publications
Promote Yourself within the Industry
Submit Your Article

Career Center: Employers
Job Posting
Free Resume Database
Volunteers Database

Career Center: Job Seekers
Now Hiring
Submit Resume
Career Training
Nurses Careers in Biopharm
Scholarship Programs
Internship Programs
Resume Editing & Interview Coaching
Volunteer for the Industry
Download IBPA Career Info Brochure

Industry Directories and Listings
Pharmaceutical Companies
Contract Research Organizations
Professional Associations
Recruiters and Staffing Agencies
Clinical Research Centers
Consulting Companies
Education & Training Institutions
Jobs and Resume Searching Directories
Research and Development Companies
List Your Company

Investor's Center
Offers
Calls

Contact IBPA
US Chapter
Canadian Chapter
European Chapter
Asian Chapter

Start Your Career in Biotech with IBPA Scholarship Programs
Untitled Document



Subscribe to our "Careers in the Biopharmaceutical Industry" newsletter:

Name*:

Email*:

City:

Country:

Phone:

To unsubscribe, click here

 

 

Ryoji Noyori

From Wikipedia, the free encyclopedia

 

Ryoji Noyori (野依良治) (born September 3, 1938) won the Nobel Prize in Chemistry in 2001.

Noyori shared half of the prize with William S. Knowles for the study of chirally catalyzed hydrogenations; the second half of the Prize went to K. Barry Sharpless for his study in chirally catalyzed oxidation reactions (Sharpless epoxidation).

Ryoji Noyori was born in Kobe, Japan. He became fascinated with chemistry at the age of 12, after hearing a presentation on nylon. He saw the power of chemistry as being the ability to "make high values from almost nothing". He became a student at Kyoto University, working as an instructor in the research group of Hotosi Nozaki before being appointed associate professor at Nagoya University. After postdoctoral work with Elias J. Corey at Harvard he returned to Nagoya, becoming a full professor in 1972. He is still based at Nagoya, though he is also now president of Riken, a multi-site national research initiative with an annual budget of $800 million.

Noyori believes strongly in the power of catalysis and of green chemistry; in a recent article he argues for the pursuit of "practical elegance in synthesis".[1] In this article he states that "our ability to devise straightforward and practical chemical syntheses is indispensable to the survival of our species." Elsewhere he has said that "Research is for nations and mankind, not for researchers themselves." He encourages scientists to be politically active- "Researchers must spur public opinions and government policies toward constructing the sustainable society in the 21st century."[2]

[edit]

 

Chemistry

Noyori is most famous for asymmetric hydrogenation using as catalysts complexes of rhodium and ruthenium, particularly those based on the BINAP ligand. Asymmetric hydrogenation of an alkene in the presence of ((S)-BINAP)Ru(OAc)2 is used for the commercial production of enantiomerically pure (97% ee) naproxen, used as an anti-inflammatory drug. The anti-bacterial agent levofloxacin is manufactured by asymmetric hydrogenation of ketones in the presence of a Ru(II) BINAP halide complex.

He has also worked on other asymmetric processes. Each year 400 000 tonnes of menthol are produced (in 94% ee) by Takasago International Co., using Noyori's method for isomerisation of allylic amines.

Manufacturing process for menthol

More recently he and Jessop have developed an industrial process for the manufacture of N,N-dimethylformamide from hydrogen, dimethylamine and supercritical carbon dioxide in the presence of RuCl2(PMe3)4 as catalyst.[3]

[edit]

 

External links

[edit]

 

References

  1. R. Noyori, Pursuing practical elegance in chemical synthesis, Chemical Communications, 2005, (14), 1807 - 1811. Abstract
  2. Keynote address, June 23, 2005, at the Second International Conference on Green and Sustainable Chemistry, Washington DC.
  3. P. G. Jessop; W. Leitner (Eds.), Chemical Synthesis using Supercritical Fluids, VCH/Wiley, Weinheim, 1999.



External links




Learn More About the Biopharmaceutical Industry and Clinical Research:


Category:


Powered by Wikipedia, the free encyclopedia. Articles were developed by IBPA volunteers.

A

B

C

D

E

F

G

I

K

L

M

N

P

Q

R

S

T


©2004 International Biopharmaceutical Association Inc., all rights reserved
Privacy Policy - Terms of Use

Google